Technology

Neurocrine

$116.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.91 (+1.66%) Today
$0.00 (0.00%) As of 10:47 AM UTC after-hours

Why Robinhood?

You can buy or sell Neurocrine and other stocks, options, and ETFs commission-free!

About NBIX

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA. The listed name for NBIX is Neurocrine Biosciences, Inc. Common Stock.

CEO
Kevin Charles Gorman
Employees
700
Headquarters
San Diego, California
Founded
1992
Market Cap
10.55B
Price-Earnings Ratio
125.90
Dividend Yield
—
Average Volume
1.20M
High Today
$117.71
Low Today
$114.09
Open Price
$115.33
Volume
647.92K
52 Week High
$136.27
52 Week Low
$72.14

Collections

NBIX News

BenzingaJan 20

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report fourth quarter and year-end 2020 financi

NBIX Earnings

$0.00
$0.47
$0.95
$1.42
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 4, After Hours

You May Also Like

GDMA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure